Skip to main content

Can GLP-1 Drugs Extend Lifespan? The Jury Is Still Out

Researchers and drug developers weigh in on if GLP-1 drugs, like semaglutide, have real potential as longevity medicines.

Written byRebecca Roberts, PhD
| 7 min read
A glowing purple glass vial casting a colorful shadow.
Register for free to listen to this article
Listen with Speechify
0:00
7:00

Few drugs have been as disruptive to the field of medicine as glucagon-like peptide-1 (GLP-1) mimics. Based on a naturally occurring human peptide, synthetic analogs of GLP-1—including blockbuster drug semaglutide or Ozempic—have not only changed the way diabetes and weight loss are managed but have also shown promise in the treatment of a range of other serious health conditions.

Michael Corley smiles wearing a navy blazer and a navy shirt with whales printed on it.

Michael Corley coauthored a study exploring the effects of GLP-1 on epigenetic aging in patients with HIV, showing that the drug can slow down the processes in people prone to accelerated aging.

Michael Corley

The latest buzz around GLP-1 is that it could help extend the human lifespan—an assertion that biohackers and self-labelled ‘longevity doctors’ immediately capitalized on. With the rapid rise of longevity medicine and a growing number of health-focused individuals seeking to reduce their biological age, off-label use of GLP-1 drugs is on the uptick.

But is there scientific evidence that medicines like semaglutide will actually make people live longer? “We're just focused on what's real and what's not and trying to get evidence and say [if] some of this is worth investigating or if there’s really no signal,” said medical scientist Michael Corley of the University of California, San Diego.

Biohackers and Influencers Jump on the GLP-1 Bandwagon

The logic behind the potential of GLP-1s in longevity is simple: Drugs like semaglutide reduce several of the key chronic illnesses and comorbidities that cause people to die early. Evidence of their pleiotropic effects has been slowly mounting since the first-generation GLP-1s were approved for the treatment of type II diabetes, with studies reporting significant improvements in lipid storage, blood pressure, blood sugar control, and cardiovascular, kidney, and lung function among patients.1

Continue reading below...

Like this story? Sign up for FREE Immunology updates:

Latest science news storiesTopic-tailored resources and eventsCustomized newsletter content
Subscribe


In presentations at the 2025 Aging Research and Drug Discovery (ARDD) conference, scientists from competing pharmaceutical giants Eli Lilly and Novo Nordisk discussed the development of GLP-1-based drugs specifically for longevity. Subsequent media reports primed the public for a wave of longevity influencers acting as GLP-1 evangelists. After all, these medicines were already approved by international regulators for the treatment of diabetes and obesity and were widely available.

At this year’s ARDD conference, Novo Nordisk scientist Nikolaj Roed shifted the focus slightly from GLP-1s increasing lifespan to increasing healthspan—the number of years a person maintains physical health, independence, and cognitive function. “Whether we can call GLP-1s longevity [drugs], we can still discuss, but it's certainly playing a role in some of the important hallmarks of aging,” said Roed in his presentation. “Going from cardiovascular [disease] to hallmarks of aging related to the immune system and inflammation, we have data indicating that semaglutide reduces the risk of composite endpoints related to infections like COVID.”

Alex Zhavoronkov, founder and chief executive officer of Insilico Medicine, is a believer. “[I’ve been] taking GLP-1 for longevity for a while,” he said. “GLP-1s do not have a full body of evidence to demonstrate the longevity effect, but I think in a year or two you're going to see papers in that area.”

Alex Zhavoronkov is wearing a black jacket, a white button-down shirt, a green lanyard, and glasses.

Alex Zhavoronkov, of Insilico Medicine, said he takes a full dose of GLP-1 for longevity, despite being a normal weight and otherwise healthy.

Insilico Medicine

While treating conditions like diabetes and obesity may prevent early mortality, researchers have been trying to find evidence that GLP-1 mimics can increase the lifespan of healthy individuals with no underlying disease. Collaborating with translational scientist Grace McComsey of Case Western Reserve University, who specializes in HIV research, Corley recently explored the effects of semaglutide on biological age in HIV patients who participated in a clinical trial.2

The primary endpoint of the Phase 2b parent trial was to assess how semaglutide affected fat distribution in the patients, but Corley and McComsey also put epigenetic clocks to work to determine if the treatment changed the DNA methylation profiles of patients’ blood—a measure of biological aging. “What it allowed us to do is basically take some of these aging-relevant markers and just ask the question: Is there any movement on those markers in the most rigorous trial design, which is a placebo-controlled trial?” Corley explained.

After eight months, Corley and his colleagues compared the effects of semaglutide to the control. “The shock to me was essentially that [the pace of aging] was slowed over the 32-week period of time,” Corley said, “[Because] this was a population of people that, generally speaking, would basically age somewhere around 64 weeks [over those 32 weeks].

Corley was quick to add that these results don’t suggest that the drug can prevent aging in healthy individuals, but rather that it can slow it down slightly in people who are prone to accelerated aging, such as those with chronic diseases. “I would say there is [enough evidence] to warrant a very rigorous follow-up study,” Corley said.

Caloric Restriction Vs. GLP-1 Treatment: Is There a Difference in Aging Impact?

Danica Chen, of the University of California, Berkeley, has studied aging for more than two decades. “The overarching hypothesis of the aging field is that if we can target the biology of aging, we might be able to prevent or treat all these unrelated diseases that are associated with aging,” Chen explained.

According to Chen, caloric restriction is one of the only proven methods to slow human aging. But even for disciplined individuals, she said, staying on a calorie-restricted diet for long periods—let alone permanently—is incredibly difficult, which is why researchers studying aging have been trying to identify interventions that mimic caloric restriction for decades. When Chen heard about the pleiotropic effects of GLP-1 and its ability to significantly reduce food intake, she was immediately intrigued.

In a preclinical study, Chen and her colleagues explored the effects of GLP-1 on the lifespan of mice.3 Taking mice aged 20 months—the equivalent of about 60 human years—the team treated the animals with either semaglutide or a negative control. “This is where our study differs from other studies,” Chen explained. “Previous studies were essentially using diseased mouse models or patients who have already been diagnosed with diseases, but our study uses natural aging mice.”

Compared to the untreated mice, those that received semaglutide did display extended lifespans by roughly 100 days, as well as improvements in several physiological functions, including motor and muscle control, and attenuations in key hallmarks of aging, such as reduced regenerative capacity of hematopoietic stem cells, declines in neurogenesis and cognitive function, and aging-associated inflammation.

To unravel whether GLP-1 had a greater effect on longevity than caloric restriction and reduced body weight, they also performed a direct comparison between animals that received semaglutide and those that were placed on a matched diet that led to the same amount of weight loss.

A black-and-white image of Danica Chen, wearing a floral top and smiling.

Danica Chen and her colleagues demonstrated that semaglutide can increase lifespan and certain biomarkers of aging in elderly mice.

Danica Chen

Many of the resulting measurements, including exercise tolerance and muscle function, were almost identical between the two groups. However, semaglutide outperformed caloric restriction when it came to factors such as cognition, glucose handling, and exploratory drive. “I was surprised, to be honest,” Chen said. “I really thought when I started the experiment, I really just thought [GLP-1] works through reduced food intake.”

Corley, who was not involved in Chen’s study, commended the team for looking at multiple biomarkers. “I'd describe this as one of the strongest pieces of preclinical evidence so far that GLP-1 receptor agonism can influence the aging process itself,” he said. However, he acknowledged that there are some key limitations to the research. “These were female mice from a single inbred strain, so we don't yet know how generalizable the longevity effect is,” Corley added.

Measuring Longevity in Clinical Trials and Remaining Questions

Since the development of first-generation GLP-1s, there have been several iterative improvements, both to combat the side effects—such as loss of lean muscle, which is particularly counterproductive in frail and elderly patients—and to expand the label indications for these drugs.

Mounjaro, for example, is a combination of both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP), while retatrutide is a triple-agonist of GLP-1, GIP, and glucagon that may help recipients retain lean muscle mass. “I think what we'll see is ultimately there will be a movement towards a GLP-1 combination that maybe could be tailored towards aging,” Corley said.

However, drug developers must first answer one outstanding question: How can they generate clinical evidence that the drug keeps people alive longer? “There is a good reason why there is no longevity drug approved, and there is good reason why we don't know if any of the current drugs work on aging,” said Zhavoronkov. “They actually might; we just don't know.”

Both Corley and Zhavoronkov remarked that a promising avenue for generating robust surrogate biomarkers for longevity in clinical trials is to use proteomics clocks, which analyze plasma proteins to identify changes in aging-related proteins and predict the risks of disease and mortality.4

At the 2026 ARDD conference, Roed said that proteomic aging clocks show improvements after treatment with GLP-1s in ongoing trials, but that the resulting difference in lifespan might only be about two years. “[That’s] presuming that you will take semaglutide for the rest of your life,” he added. Representatives from Eli Lilly and Novo Nordisk declined to comment for this article.

Despite mounting evidence, several key questions remain: Assuming there are benefits for longevity that could not be gained through caloric restriction, would GLP-1 treatment still work in metabolically healthy people with no comorbidities? How early do people need to start taking GLP-1s if they want to maximize longevity? What dose is appropriate for people who are otherwise healthy? And finally, would patients really need to take these drugs indefinitely, as Roed suggested?

Corley and his coauthors are currently trying to answer the latter question. “[My collaborator Grace McComsey] sees this clinically a lot, that when people stop their GLP-1s, the weight comes back, and some of these [comorbidities] come back,” Corley explained. “We're actually doing a follow-up study right now at 52 weeks with the same people in this initial study to see if it reverts.”

Interestingly, Corley added, there are a number of people who seem resistant to the effects of GLP-1s. “That's [another] big outstanding question,” he said. For Chen, the field needs to take a more personalized approach to optimize people’s health and longevity. “Everyone's metabolism is different, so maybe we're not really [going to] just have a fixed dose for everyone, but rather individualize it,” said Chen.

“The critical next step is identifying which GLP-1–based therapies reproduce [the effects seen in Chen’s study] in humans, in which patients, and whether the people most likely to benefit can be identified using molecular and functional markers of aging,” Corley said. “The jury is still out on longevity. I don't see this extending life beyond what we would normally see humans capable of. My view is still that we need clinical trial evidence in humans showing that these drugs are actually modifying the biology of aging and improving feel, function, and survival rather than simply reducing several major age-related disease risks.”

Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

  • Rebecca Roberts,PhD

    Rebecca Roberts is a science writer and communicator. She earned her PhD in molecular biology from the University of the Sunshine Coast in Australia and completed a two-year postdoctoral fellowship at Lund University in Sweden. Her writing focuses on gene editing technology, cell and gene therapies, and the regulatory space.

    View Full Profile

Related Topics

You might also be interested in...
Loading Next Article...
You might also be interested in...
Loading Next Article...
November digest cover
November 2026

Chemistry Meets Arcade Combat in “Reaction Rumble” Game

Choose your fighter! Enter the arena as chemical elements and dole out moves inspired by real-world reactions in this educational browser-based game.

View this Issue
From Pilot to Practice: Advancing Regulatory Reliance

From Pilot to Precedent: A Year of Regulatory Innovation through PRISM and What it Means for Cloud Adoption in Regulatory Submissions

DNAnexus
Thumbnail

Make It Local, Make It Last: The Evolution of mRNA Protein Replacement Therapy

Improving Western Blot Analysis of Biofluid Samples

Improving Western Blot Analysis of Biofluid Samples

Bio-Rad
Reducing AAV Sample Consumption With Multiwavelength SV-AUC

Reducing AAV Sample Consumption With Multiwavelength SV-AUC

​Beckman Coulter

Products

Sino Logo

Sino Biological Introduces AI-Trusted and Qualified Target Protein Collections for AI-Driven  Discovery

Sino Biological Logo

Sino Biological Advances AI-Designed Molecule Validation with 4RISE™

Illustrated floating metabolites and molecules

Metabolon Verus™ Kit: Metabolomics Profiling Kit

Metabolon
Abstract image of circles and concentric lines on a blue and pink background.

MX Analytical and Precision Balances: Effortless Weighing and Secure Data Handling

Mettler